COMPASS Pathways (CMPS) is having a very good morning. Shares rocketed higher in premarket trading Tuesday after the biotech company announced that its psilocybin-based therapy successfully hit the primary endpoint in a Phase 3 trial for treatment-resistant depression. This is the kind of news that gets investors excited, particularly in a space where effective treatments are frustratingly scarce.

What the Trial Results Actually Show

Here's what matters: In the 25 mg arm of the COMP006 trial, COMPASS saw a statistically significant reduction in symptom severity for treatment-resistant depression. We're talking about real, measurable improvements in people who haven't responded to conventional treatments.

The numbers are compelling. Two doses of COMP360 at 25 mg versus 1 mg produced a highly statistically significant and clinically meaningful reduction in symptom severity, with a mean difference of -3.8 when comparing 25 mg to 1 mg (p<0.001). That's statistics-speak for "this really worked."

Even better, a clinically meaningful reduction in MADRS scores (≥ 25%) showed up in a significant chunk of participants in the 25mg arm across both trials: 25% in COMP005 and 39% in COMP006. COMP360, by the way, is the company's proprietary formulation of psilocybin, the psychedelic compound that's been generating serious scientific interest lately.

On the safety front, the data suggest that COMP360 is generally well-tolerated. Most treatment-emergent adverse events were mild or moderate, which is exactly what you want to see when you're trying to get a drug approved. Speaking of which, COMPASS is now advancing discussions with the FDA to submit a New Drug Application in Q4 2026. If successful, this could open the door to genuinely new treatment options for people who've run out of alternatives.

This isn't COMPASS's first rodeo with positive Phase 3 data. Back in June 2025, the company shared results from the COMP005 trial, where a single dose of COMP360 demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity compared to placebo.

Technical Picture

The stock is currently trading 31.15% above its 12-month performance, which tells you momentum has been building. Shares are positioned closer to their 52-week highs than lows, reflecting bullish sentiment among investors who apparently saw this coming.

The technical indicators are sending mixed signals, though. The RSI sits at a neutral level, while the MACD is below its signal line, suggesting some bearish pressure. This combination indicates the stock hasn't quite established a clear trend direction yet, despite today's pop.

Key levels to watch: resistance at $8.00, support at $6.00.

What the Analysts Think

Wall Street is generally optimistic here. The stock carries a Buy rating with an average price target of $18.15. Recent analyst moves include:

• RBC Capital: Outperform (Raises Target to $21)
• Morgan Stanley: Overweight (Raises Target to $11)
• BTIG: Buy (Raises Target to $14)

ETF Exposure

If you're looking for broader exposure to the psychedelics space, the ADVISORSHARES PSYCHEDELICS ETF (PSIL) holds COMPASS at an 8.62% weight.

Price Action: COMPASS Pathways shares were up 23.06% at $7.15 during premarket trading on Tuesday.